Table 5.
Serious adverse events and adverse events (SAE/AE).
| Patient ID | Age Months/ M/F |
Allergic Reactions at Step | Minutes after Intake | Medication, According to National Anaphylaxis Protocol | Stopped at Dose/Outcome * | SAE/AE Sampson Scale |
|---|---|---|---|---|---|---|
| 111002 | 13/M | Step 2: | Step 2: | Step 2: | Dose: 2/ After 5 h released from hospital |
SAE 4 |
| Eczema lips (15′ diminished) | 2 min | Adrenaline auto-injector (0.15 mg), Xyzal suspension (2.5 mg), dexamethason (4 mg) |
||||
| Step 2 repeated: Stridor, cough, crying | Step 2 repeated: 15 min | |||||
| 555004 | 6/F | Step 6: | Step 6: | None | Full challenge/ <24 h |
AE/2 |
| Eczema feet, back, belly; | 15 min; | |||||
| vomiting, itch, eczema face, diarrhea | 6–9 h | |||||
| 888004 | 37/M | Dry cough, stridor | Step 4: 5–10 min | Step 4: | Dose: 4/ After 2 h released from hospital |
AE/4 |
| Aerius suspension (2.5 mL) | ||||||
| 888005 | 8/M | Step | Step | Step 5: | Dose: 5/ After 2 h released from hospital |
AE/3 |
| 1: Sneezing, erythema chin | 1 repeated: 5 min | Aerius-suspension (2x 2.2 mL) | ||||
| 5: Cough, redness face, nausea | 5: 10–15 min | |||||
| 999001 | 11/M | Step: | Step 3: 25 min | Step 3: Aerius suspension (2.5 mL) and prednisone | Dose: 3/ 15 min no more wheezing |
AE/3 |
| 2: increased eczema | ||||||
| 3: Sneezing, cough, runny nose, increased eczema, wheezing | ||||||
| 999002 | 10/F | Step: | Step: | none | Dose: 6/ Not specified |
AE/3 |
| 4: Sneezing, cough, starting urticaria | 4: 15–20 min | |||||
| 5: Runny nose, redness face, urticaria | 5: directly | |||||
| 6: (after pause): urticaria | 6: after 10 min | |||||
| 999004 | 10/F | Step: | Step: | Step 2: Aerius suspension (2.5 mL) and 1.6 mL prednisone | Dose: 2/ After 4 h released from hospital |
AE/2 |
Abbreviations: Step 1 (10 mg), step 2 (30 mg), step 3 (100 mg), step 4 (300 mg), step 5 (1000 mg), step 6 (3000 mg). * Hours until symptoms disappeared; SAE: serious adverse events; AE: adverse events; M/F: male/female; mL: millilitres; min: minutes.